WO2008067119A3 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
WO2008067119A3
WO2008067119A3 PCT/US2007/083568 US2007083568W WO2008067119A3 WO 2008067119 A3 WO2008067119 A3 WO 2008067119A3 US 2007083568 W US2007083568 W US 2007083568W WO 2008067119 A3 WO2008067119 A3 WO 2008067119A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
compositions
azaindole derivatives
medicaments
compounds
Prior art date
Application number
PCT/US2007/083568
Other languages
French (fr)
Other versions
WO2008067119A2 (en
Inventor
Jun Tang
Toshihiro Hamajima
George Maclean Adjabeng
Original Assignee
Smithkline Beecham Corp
Jun Tang
Toshihiro Hamajima
George Maclean Adjabeng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Jun Tang, Toshihiro Hamajima, George Maclean Adjabeng filed Critical Smithkline Beecham Corp
Publication of WO2008067119A2 publication Critical patent/WO2008067119A2/en
Publication of WO2008067119A3 publication Critical patent/WO2008067119A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to azaindole derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such azaindole derivatives are potentially useful in the treatment of diseases associated with inappropriate c-Met activity and/or B-Raf kinase activity. A compound of Formula (I):
PCT/US2007/083568 2006-11-27 2007-11-05 Novel compounds WO2008067119A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86724606P 2006-11-27 2006-11-27
US60/867,246 2006-11-27

Publications (2)

Publication Number Publication Date
WO2008067119A2 WO2008067119A2 (en) 2008-06-05
WO2008067119A3 true WO2008067119A3 (en) 2008-08-21

Family

ID=39468597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083568 WO2008067119A2 (en) 2006-11-27 2007-11-05 Novel compounds

Country Status (1)

Country Link
WO (1) WO2008067119A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612196T3 (en) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI484962B (en) 2009-05-22 2015-05-21 Incyte Corp 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane-or heptane-nitrile as jak inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010300930B2 (en) * 2009-09-30 2014-09-11 Merck Sharp & Dohme (Uk) Limited Crystalline hydrochloride salts of c-MET kinase inhibitors
KR102354472B1 (en) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5876146B2 (en) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
HUE055894T2 (en) 2012-11-15 2021-12-28 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PE20151902A1 (en) 2013-03-06 2015-12-26 Incyte Corp PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
DK3746429T3 (en) 2018-01-30 2022-05-02 Incyte Corp PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON)
IL277538B1 (en) 2018-03-30 2024-05-01 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174889B1 (en) * 1996-07-13 2001-01-16 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174889B1 (en) * 1996-07-13 2001-01-16 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHIERING ET AL.: "Crystal Structure of the Tyrosine Kinase Domaine of the Hepatocyte Growth Factor Receptor c-Met and Its Complex with the Microbial Alkaloid K-252A", PROC. NTNL. ACAD. SCI., vol. 100, October 2003 (2003-10-01), pages 12654 - 12659, XP002491742 *

Also Published As

Publication number Publication date
WO2008067119A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2008067119A3 (en) Novel compounds
MX2009010047A (en) Chemical compounds.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MX2009010045A (en) Chemical compounds.
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
TW200745067A (en) Novel compounds
WO2004112719A3 (en) Chemical compounds
WO2009016410A3 (en) Chemical compounds 831
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
WO2006077025A3 (en) Morpholines as 5ht2c agonists
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
TW200745084A (en) Novel compounds
TW200626593A (en) Novel compounds
TW200738659A (en) Novel compounds
WO2007083060A3 (en) Novel chalcone derivatives with antimitotic activity
WO2007130821A3 (en) Mglur5 modulators ii
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
MX2009000768A (en) Macrocyclic lactams.
WO2007018941A3 (en) Pyrimidyl-thiophene derivatives
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
WO2006044753A3 (en) Chemical compounds
WO2008033930A3 (en) Vinca derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07863866

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07863866

Country of ref document: EP

Kind code of ref document: A2